Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
At Terra, we like to peek into our body and physiology through the lens of our wearables
If thyroid cancer happens, it may be deadly if not found and treated early
However, if side effects become severe, its essential to consult a healthcare provider
For pipettes, use filtered sterile tips and avoid touching the part of the tip that will dispense into the solution
Semaglutide trial shows promise for schizophrenia, prediabetes, and obesity Summary of the HISTORI Randomized Clinical Trial The HISTORI trial, published in *JAMA Psychiatry* on September 3, 2025 (doi:10.1001/jamapsychiatry.2025.2332), is a multicenter, double-blind, placebo-controlled randomized clinical trial evaluating the efficacy and safety of once-weekly subcutaneous semaglutide (a glucagon-like peptide-1 receptor agonist) as an adjunct to second-generation antipsychotic treatment in adults with schizophrenia spectrum disorders, prediabetes (HbA1c 5.7%-6.4%), and overweight/obesity (BMI 27 kg/m)
US$ 26.54
US$ 27.86
US$ 25.26
US$ 21.21
